Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer
Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer
复制标题
DOI：
10.1007/s00259-012-2291-9
复制
发表时间：
2013-02-01
影响因子：
9.1
通讯作者：
Johansson, Silvia
中科院分区：
文献类型：
--
作者：
Sorensen, Jens;Owenius, Rikard;Johansson, Silvia
[F-18]氟昔洛夫碱（抗[F-18]FACBC）是一种合成氨基酸，用于PET评估临床常规肿瘤代谢的合成代谢成分。该1期临床试验评估了[F-18]氟氯梵在患者体内的安全性、示踪剂稳定性和摄取动力学。本文对6例活检证实的前列腺癌患者进行了3-T MRI和PET/CT检查。在注射418 +/- 10 MBq的示踪剂后，所有患者接受盆腔动态[F-18]氟氯盆PET/CT扫描，时间长达120分钟，同时进行血液放射性采样。使用标准化摄取值（suv）和室室模型评估肿瘤和正常组织的摄取动力学。MRI确定的肿瘤沉积在PET上清晰可见。尿排泄少，正常组织背景低。肿瘤血液中[F-18]氟氯洛夫的摄取迅速，注射后1 - 15分钟，肿瘤与正常组织的对比最高，注射后90分钟，平均肿瘤摄取减少65%。单室模型很好地拟合了示踪动力学。早期suv与内流速率常数（K(1)）和示踪剂的分布体积（V (T)）都有良好的相关性。没有示踪代谢物形成的迹象。该产品在所有患者中耐受性良好，无明显不良事件。[F-18]氟昔洛夫在前列腺癌沉积物中有很高的吸收，在人体中使用似乎是安全的。该制剂在体内稳定，产量稳定。早期的成像窗口似乎能提供最好的视觉效果。SUV的测量数据可以捕捉到大多数可以从更先进的模型中获得的动力学信息，这可能会简化未来研究中的量化。
[F-18]Fluciclovine (anti-[F-18]FACBC) is a synthetic amino acid developed for PET assessment of the anabolic component of tumour metabolism in clinical routine. This phase 1 trial evaluated the safety, tracer stability and uptake kinetics of [F-18]fluciclovine in patients.Six patients with biopsy-proven prostate cancer were investigated with 3-T MRI and PET/CT. All underwent dynamic [F-18]fluciclovine PET/CT of the pelvic area for up to 120 min after injection of 418 +/- 10 MBq of tracer with simultaneous blood sampling of radioactivity. The kinetics of uptake in tumours and normal tissues were evaluated using standardized uptake values (SUVs) and compartmental modelling.Tumour deposits as defined by MRI were clearly visualized by PET. Urine excretion was minimal and normal tissue background was low. Uptake of [F-18]fluciclovine in tumour from the blood was rapid and the tumour-to-normal tissue contrast was highest between 1 and 15 min after injection with a 65 % reduction in mean tumour uptake at 90 min after injection. A one-compartment model fitted the tracer kinetics well. Early SUVs correlated well with both the influx rate constant (K (1)) and the volume of distribution of the tracer (V (T)). There were no signs of tracer metabolite formation. The product was well tolerated in all patients without significant adverse events.[F-18]Fluciclovine shows high uptake in prostate cancer deposits and appears safe for use in humans. The production is robust and the formulation stable in vivo. An early imaging window seems to provide the best visual results. SUV measurements capture most of the kinetic information that can be obtained from more advanced models, potentially simplifying quantification in future studies.